INTRODUCTION: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments. METHODS:Thirteen postmenopausal women (>or=6 yr since menopause) were predosed with 41Ca iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for 41Ca/Ca analysis by accelerator mass spectrometry. RESULTS:Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary 41Ca/Ca ratios. CONCLUSIONS:Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary 41Ca excretion from prelabeled bone.
RCT Entities:
INTRODUCTION: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments. METHODS: Thirteen postmenopausal women (>or=6 yr since menopause) were predosed with 41Ca iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for 41Ca/Ca analysis by accelerator mass spectrometry. RESULTS: Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary 41Ca/Ca ratios. CONCLUSIONS: Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary 41Ca excretion from prelabeled bone.
Authors: Apurva K Srivastava; Elizabeth L Vliet; E Michael Lewiecki; Michael Maricic; Alex Abdelmalek; Oscar Gluck; David J Baylink Journal: Curr Med Res Opin Date: 2005-07 Impact factor: 2.580
Authors: David J Cai; Yongdong Zhao; Jennifer Glasier; Diane Cullen; Stephen Barnes; Charles H Turner; Meryl Wastney; Connie M Weaver Journal: J Bone Miner Res Date: 2004-12-27 Impact factor: 6.741
Authors: S T Harris; E F Eriksen; M Davidson; M P Ettinger; A H Moffett; D J Baylink; C E Crusan; A A Chines Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: L G Raisz; B Wiita; A Artis; A Bowen; S Schwartz; M Trahiotis; K Shoukri; J Smith Journal: J Clin Endocrinol Metab Date: 1996-01 Impact factor: 5.958
Authors: Connie M Weaver; Stephen Barnes; J Michael Wyss; Helen Kim; Dorothy M Morré; D James Morré; James E Simon; Mary Ann Lila; Elsa M Janle; Mario G Ferruzzi Journal: Am J Clin Nutr Date: 2008-02 Impact factor: 7.045
Authors: Stephen Barnes; Diane F Birt; Barrie R Cassileth; William T Cefalu; Floyd H Chilton; Norman R Farnsworth; Ilya Raskin; Richard B van Breemen; Connie M Weaver Journal: Am J Clin Nutr Date: 2008-02 Impact factor: 7.045
Authors: George S Jackson; Darren J Hillegonds; Paul Muzikar; Brent Goehring Journal: Nucl Instrum Methods Phys Res B Date: 2013-10-15 Impact factor: 1.377
Authors: J M K Cheong; N S Gunaratna; G P McCabe; G S Jackson; A Kempa-Steczko; C M Weaver Journal: Osteoporos Int Date: 2010-05-18 Impact factor: 4.507
Authors: James J Miller; Susanta K Hui; George S Jackson; Sara P Clark; Jane Einstein; Connie M Weaver; Maryka H Bhattacharyya Journal: Appl Radiat Isot Date: 2013-04-17 Impact factor: 1.513
Authors: Ho Seok Kwak; So Young Park; Mi Gyeong Kim; Chang Hoon Yim; Hyun Koo Yoon; Ki Ok Han Journal: J Korean Med Sci Date: 2009-09-23 Impact factor: 2.153